Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi PharmaTech and Foundation Partner to Offer Cancer Test in China

publication date: Oct 22, 2014
WuXi PharmaTech formed a collaboration with Foundation Medicine of Cambridge, MA that will offer the FoundationOne® assay in China. The assay tests for genetic abnormalities associated with cancer to determine the best treatment. For pharmas undertaking China clinical trials, the personalized medicine test will identify target patient populations. WuXi, whose venture arm was an early investor in Foundation, will perform the laboratory component of the assay at its Shanghai Genome Center. More details....

Stock Symbols: (NYSE: WX) (NSDQ: FMI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital